174 related articles for article (PubMed ID: 38263523)
1. Cardio-renoprotective effects of SGLT2 inhibitors-the role of anaemia correction.
Locatelli F; Del Vecchio L
Nephrol Dial Transplant; 2024 May; 39(6):904-906. PubMed ID: 38263523
[No Abstract] [Full Text] [Related]
2. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.
Heerspink HJL; Kosiborod M; Inzucchi SE; Cherney DZI
Kidney Int; 2018 Jul; 94(1):26-39. PubMed ID: 29735306
[TBL] [Abstract][Full Text] [Related]
3. Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis.
Usman MS; Siddiqi TJ; Memon MM; Khan MS; Rawasia WF; Talha Ayub M; Sreenivasan J; Golzar Y
Eur J Prev Cardiol; 2018 Mar; 25(5):495-502. PubMed ID: 29372664
[TBL] [Abstract][Full Text] [Related]
4. Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes: A meta-analysis.
Zou CY; Liu XK; Sang YQ; Wang B; Liang J
Medicine (Baltimore); 2019 Dec; 98(49):e18245. PubMed ID: 31804352
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists in Type 2 diabetes.
Med Lett Drugs Ther; 2019 Feb; 61(1566):26-28. PubMed ID: 30845101
[No Abstract] [Full Text] [Related]
6. Glucose-Lowering and Metabolic Effects of SGLT2 Inhibitors.
Mordi IR; Lang CC
Heart Fail Clin; 2022 Oct; 18(4):529-538. PubMed ID: 36216483
[TBL] [Abstract][Full Text] [Related]
7. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiovascular and Metabolic Outcomes in Patients Without Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials.
Teo YH; Teo YN; Syn NL; Kow CS; Yoong CSY; Tan BYQ; Yeo TC; Lee CH; Lin W; Sia CH
J Am Heart Assoc; 2021 Feb; 10(5):e019463. PubMed ID: 33625242
[TBL] [Abstract][Full Text] [Related]
8. SGLT2 Inhibitors Improve All-Cause and Cardiovascular Mortality in Patients Regardless of Diabetes or Heart Failure Status.
Shaughnessy AF
Am Fam Physician; 2021 May; 103(10):630-631. PubMed ID: 33983007
[No Abstract] [Full Text] [Related]
9. Do we have enough evidence to support the use of SGLT2 inhibitors for MACE reduction in patients with advance kidney disease?
Doshi R; Meghji Z; Kumar A; Shariff M; Adalja D
Eur J Intern Med; 2019 Dec; 70():e25-e26. PubMed ID: 31685351
[No Abstract] [Full Text] [Related]
10. Strategies for Appropriate Selection of SGLT2-i vs. GLP1-RA in Persons with Diabetes and Cardiovascular Disease.
Dhindsa DS; Mehta A; Sandesara PB; Thobani A; Brandt S; Sperling LS
Curr Cardiol Rep; 2019 Jul; 21(9):100. PubMed ID: 31352613
[TBL] [Abstract][Full Text] [Related]
11. Benefit of Dapagliflozin When Used With Cardiovascular Medications in Patients With Type 2 Diabetes.
Slomski A
JAMA; 2022 Sep; 328(9):817. PubMed ID: 36066528
[No Abstract] [Full Text] [Related]
12. SGLT2 inhibitors in people with and without T2DM.
Khunti K
Nat Rev Endocrinol; 2021 Feb; 17(2):75-76. PubMed ID: 33293703
[No Abstract] [Full Text] [Related]
13. Evolution of Type 2 Diabetes Management from a Glucocentric Approach to Cardio-Renal Risk Reduction: The New Paradigm of Care.
Jacob S; Krentz AJ; Deanfield J; Rydén L
Drugs; 2021 Aug; 81(12):1373-1379. PubMed ID: 34302636
[TBL] [Abstract][Full Text] [Related]
14. The anti-hypertensive effects of sodium-glucose cotransporter-2 inhibitors.
Kugathasan L; Dubrofsky L; Advani A; Cherney DZI
Expert Rev Cardiovasc Ther; 2023 Jan; 21(1):15-34. PubMed ID: 36524239
[TBL] [Abstract][Full Text] [Related]
15. Introduction.
Chilton R
Am J Med; 2017 Jun; 130(6S):S1-S3. PubMed ID: 28526180
[No Abstract] [Full Text] [Related]
16. Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk.
Giorgino F; Vora J; Fenici P; Solini A
Cardiovasc Diabetol; 2020 Nov; 19(1):196. PubMed ID: 33222693
[TBL] [Abstract][Full Text] [Related]
17. Effect of SGLT2 inhibitors on anemia and their possible clinical implications.
Cases A; Cigarrán S; Luis Górriz J; Nuñez J
Nefrologia (Engl Ed); 2024; 44(2):165-172. PubMed ID: 38604895
[TBL] [Abstract][Full Text] [Related]
18. SGLT2 inhibitors: practical considerations and recommendations for cardiologists.
Opingari E; Partridge ACR; Verma S; Bajaj HS
Curr Opin Cardiol; 2018 Nov; 33(6):676-682. PubMed ID: 30148719
[TBL] [Abstract][Full Text] [Related]
19. The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments.
Garcia-Ropero A; Badimon JJ; Santos-Gallego CG
Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1287-1302. PubMed ID: 30463454
[TBL] [Abstract][Full Text] [Related]
20. SGLT2 Inhibitors and Cardiovascular Outcomes: Do they Differ or there is a Class Effect? New Insights from the EMPA-REG OUTCOME trial and the CVD-REAL Study.
Kyriakos G; Quiles-Sanchez LV; Garmpi A; Farmaki P; Kyre K; Savvanis S; Antoniou VK; Memi E
Curr Cardiol Rev; 2020; 16(4):258-265. PubMed ID: 31362691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]